Biochemical Toxicology of Chemical Teratogenesis

References

• Anderson M. E., Powrie F., Puri R. N., Meister A. Glutathione monoethyl ester: preparation, uptake by tissues, and conversion to glutathione. Arch. Biochem. Biophys. 1985; 239: 538–548
   PubMed Web of Science ®Google Scholar
• Anderson M. E., Meister A. Glutathione monoesters. Anal. Biochem. 1989; 183: 16–20
   PubMed Web of Science ®Google Scholar
• Arlen R. R., Wells P. G. Effect of the cyclooxygenase inhibitor acetylsalicylic acid on thalidomide teratogenicity in New Zealand white rabbits. FASEB J. 1989; 3: A1025
   Google Scholar
• Arlen R. R., Wells P. G. Inhibition of thalidomide teratogenicity by acetylsalicylic acid: evidence for prostaglandin H synthetase-catalysed bioactivation of thalidomide to a teratogenic reactive intermediate in the New Zealand white rabbit. J. Pharmacol. Exp. Ther. 1996, In press
   PubMedGoogle Scholar
• Arlen R. R., Wells P. G. Extracellular thiol-disulfide status reflecting chemical tox-icity mediated via oxidative stress: validation with paraquat and t-butylhydroperoxide, and implications for phenytoin and thalidomide teratogenicity. FASEB J. 1990; 4: A608
   Google Scholar
• Arlen R. A., Wells P. G. Submitted. Extracellular thiol-disulfide status reflecting chemical toxicity mediated via oxidative stress: validation with paraquat and t-butylhydroperoxide, and implications for phenytoin and thalidomide teratogenicity.
   Google Scholar
• Ashby R., Davis L., Dewhurst B. B., Espinal R., Penn R. N., Upshall D. G. Aspects of the teratology of cyclophosphamide (NSC-26271). Cancer Treat. Rep. 1976; 60: 477–482
   PubMedGoogle Scholar
• Balling R., Haaf M., Maydl R., Metzler M., Beier H. M. Oxidative and conjugative metabolism of diethylstilbestrol by rabbit pre-implantation embryos. Dev. Biol. 1985; 109: 370–378
   PubMed Web of Science ®Google Scholar
• Benson A. J., Martin C. N., Garner R. C. N-(2-Hydroxyethyl)-N[2-(7-guaninyl) ethyl], the putative major DNA adduct of cyclophosphamide in vitro and in vivo in the rat. Biochem. Pharmacol. 1988; 37: 2979–2985
   PubMedGoogle Scholar
• Bochert G., Platzek R., Rahm U., Webb I. Some new aspects in the study of DNA alkylation in embryonic and fetal tissues. Role of Pharmacokinetics in Prenatal and Perinatal Toxicology, D. Neubert, H.-J. Merker, H. Nau, J Langman. Georg Thieme Verlag, Stuttgart 1978; 253–261
   Google Scholar
• Boyd J. A., Harvan D. J., Eling T. E. The oxidation of 2-aminofluorene by prostaglandin endoperoxide synthetase. J. Biol. Chem. 1983; 258: 8246–8254
   PubMed Web of Science ®Google Scholar
• Boyd J. A., Eling T. E. Prostaglandin H synthase-catalyzed metabolism and DNA binding of 2-naphthylamine. Cancer Res. 1987; 47: 4007–4014
   PubMedGoogle Scholar
• Boyd J. A., Eling T. E. Evidence for a one-electron mechanism of 2-aminofluorene oxidation by prostaglandin H synthase and horseradish peroxidase. J. Biol. Chem. 1984; 259: 13885–13896
   PubMedGoogle Scholar
• Braun A. G., Harding F. A., Weinreb S. L. Teratogen metabolism: thalidomide activation is mediated by cytochrome P-450. Toxicol. Appl. Pharmacol. 1986; 82: 175–179
   PubMed Web of Science ®Google Scholar
• Brierly C. H., Burchell B. Human UDP-glucuronosyl transferases: chemical defence, jaundice and gene therapy. Bioessays 1993; 15: 749–754
   PubMedGoogle Scholar
• Buehler B. A. Epoxide hydrolase activity and fetal hydantoin syndrome. Proc. Greenwood Genet. Cent. 1984; 3: 109–110
   Google Scholar
• Buehler B. A., Delimont D., VanWaes M., Finnell R. H. Prenatal prediction of risk of the fetal hydantoin syndrome. N. Engl. J. Med. 1990; 322: 1567–1572
   PubMed Web of Science ®Google Scholar
• Burchell B. Observations of uridine diphos-phate glucuronyltransferase activity towards oestriol and xenobiotics in developing and cultured tissues from mouse and man. Biochem. Soc. Trans. 1973; 1: 1212–1214
   PubMedGoogle Scholar
• Burchell B., Dutton G. J. Delayed induction by phenobarbital of UDP-glucuro-nyltransferase activity towards bilirubin in fetal liver. Biol. Neonate 1975; 26: 122–128
   PubMedGoogle Scholar
• Burchell B., Coughtrie M. W. H. UDP-glucuronosyltransferase. Pharmacol. Ther. 1989; 43: 261–289
   PubMed Web of Science ®Google Scholar
• Burchell B., Coughtrie M. W. H., Jansen P. L. M. Function and regulation of UDP-glucuronosyltransferase genes in health and liver disease: report of the seventh international workshop on glucuronidation, September 1993, Pitlochry, Scotland. Hepatology 1994; 20: 1622–1630
   PubMed Web of Science ®Google Scholar
• Byczkowski J. Z., Kulkarni A. P. Lipoxygenase-catalyzed epoxidation of benzo[a]pyrene-7,8-dihydrodiol. Biochem. Biophys. Res. Commun. 1989; 159: 1199–1205
   PubMed Web of Science ®Google Scholar
• Carpenter S. P., Raucy J. L. CYP2E1: a putative role in chemical-mediated teratoge-nesis. Proc. Int. Soc. Study Xenobiot. 1995; 8: 238
   Google Scholar
• Chung C. S., Myrianthopoulos N. C. Factors affecting risks of congenital malformations. The National Foundation March of Dimes. Original Articles Series. 1975; Vol. 11.
   Google Scholar
• Chung A.-S., Maines M. D., Reynolds W. A. Inhibition of the enzymes of glutathione metabolism by mercuric chloride in the rat kidney: reversal by selenium. Biochem. Pharmacol. 1982; 31: 3093–3100
   PubMed Web of Science ®Google Scholar
• Datta K., Kulkarni A. P. Oxidative metabolism of aflatoxin B1 by lipoxygenase purified from human term placenta and intrau-terine conceptal tissues. Teratology 1994; 50: 311–317
   PubMedGoogle Scholar
• Degen G. H., Eling T. E., McLachlan J. A. Oxidative metabolism of diethylstil-bestrol by prostaglandin synthetase. Cancer Res. 1982; 42: 919–923
   PubMed Web of Science ®Google Scholar
• DeSesso J. M. Cell death and free radicals: a mechanism for hydroxyurea teratogenesis. Med. Hypoth. 1979; 5: 937–951
   PubMedGoogle Scholar
• DeSesso J. M., Scialli A. R., Goeringer G. C. D-Mannitol, a specific hydroxyl free radical scavenger, reduces the developmental toxicity of hydroxyurea in rabbits. Teratology 1994; 49: 248–259
   PubMedGoogle Scholar
• DeSesso J. M., Goeringer G. C. Ethoxyquin and nordihydroguaiaretic acid reduce hydroxyurea developmental toxicity. Reprod. Toxicol. 1990; 4: 267–275
   PubMedGoogle Scholar
• Dierickx P. J. In vitro inhibition of the soluble glutathione s-transferases from rat liver by heavy metals. Enzyme 1982; 27: 25–32
   PubMedGoogle Scholar
• Dirven H. A., Venekamp A. M.J. C., van Ommen B., Van Bladeren P. J. The interaction of glutathione with 4-hydroxy-cyclophos-phamide and phosphoramide mustard, studied by 32P nuclear magnetic resonance spectros-copy. Chem. Biol. Interact. 1994; 93: 185–196
   PubMed Web of Science ®Google Scholar
• Doecke C. J., Veronese M. E., Pond S. M., Miners J. O., Birkett D. J., Sansom L. N., McManus M. E. Relationship between phenytoin and tolbutamide hydroxylations in human liver microsomes. Br. J. Clin. Pharmacol. 1991; 1: 125–130
   Google Scholar
• Dutton G. J. Glucuronide-forming enzymes. Handbook of Experimental Pharmacology Brodie and Gillette. Springer-Verlag., Berlin 1971; Vol. 28: 378–400, 2
   Google Scholar
• Edmonds L., Hatch M., Holmes L., Kline J., Letz G., Levin B., Miller R., Shrout P., Stein Z., Warburton D., Weinstock M., Whorton R. D., Wyrobek A. Report of panel II: guidelines for reproductive studies in exposed human populations. Guidelines for Studies of Human Populations Exposed to Mutagenic and Reproductive Hazards, A. D. Bloom. March of Dimes Birth Defects Foundation, White Plains, NY 1981
   Google Scholar
• Eriksson U. J., Borg L. A. H. Protection by free oxygen radical scavenging enzymes against glucose-induced embryonic malformations in vitro. Diabetologia 1991; 34: 325–331
   PubMed Web of Science ®Google Scholar
• Eriksson U. J., Borg L. A. H. Diabetes and embryonic malformations: role of sub-strate-induced free-oxygen radical production for dysmorphogenesis in cultured rat embryos. Diabetes 1993; 42: 411–419
   PubMed Web of Science ®Google Scholar
• Fantel A. G., Greenaway J. C., Juchau M. R., Shepard T. H. Teratogenic bioactivation of cyclophosphamide in vitro. Life Sci. 1979; 25: 67–72
   PubMed Web of Science ®Google Scholar
• Fantel A. G. Culture of whole rodent embryos in teratogen screening. Teratogen. Carcinogen. Mutagen. 1982; 2: 231–234
   PubMedGoogle Scholar
• Fantel A. G., Pereson R. E., Tracy J. W., Juchau M. R. Niridazole metabolism by rat embryos in vitro. Teratology 1988; 37: 213–221
   PubMedGoogle Scholar
• Fantel A. G., Barber C. V., Carda M. B., Tumbic R. W., Mackler B. Studies of the role of ischemia/reperfusion and superoxide anion radical production in the teratogenicity of cocaine. Teratology 1992; 46: 293–300
   PubMedGoogle Scholar
• Faustman-Watts E. M., Greenaway J. C., Namkung M. J., Fantel A. G., Juchau M. R. Teratogenicity in vitro of 2-acetylaminofluorene: role of biotransforma-tion. Teratology 1983; 27: 19–28
   PubMedGoogle Scholar
• Faustman-Watts E. M., Giachelli C. M., Juchau M. R. Carbon monoxide inhibits monooxygenation by the conceptus and embryotoxic effects of proteratogens in vitro. Toxicol. Appl. Pharmacol. 1986; 83: 590–595
   PubMed Web of Science ®Google Scholar
• Filler R., Lew K. J. Developmental onset of mixed-function oxidase activity in preimplantation mouse embryos. Proc. Natl. Acad. Sci. U.S.A. 1981; 78: 6991–6995
   PubMed Web of Science ®Google Scholar
• Finnell R. H., Chernoff C. F. Gene-teratogen interactions: an approach to understanding the metabolic basis of birth defects. Pharmacokinetics in Teratogenesis, H. Nau, W. Scott. CRC Press., New York 1987; Vol. 2.: 97–109
   Google Scholar
• Finnell R. H., Kerr B. M., van Waes M., Steward R. L., Levy R. H. Protection from phenytoin-induced congenital malformations by coadministration of the antiepileptic drug stiripentol in a mouse model. Epilepsia 1994; 35: 141–148
   PubMed Web of Science ®Google Scholar
• Fort D. J., Stover E. L., Rayburn J. R., Huli M., Bantle J. A. Evaluation of the developmental toxicity of trichloroeth-ylene and detoxification metabolites using Xenopus. Teratogen. Carcinogen. Mutagen. 1993; 13: 35–45
   PubMedGoogle Scholar
• Frank A. A., Collier J. M., Forsyth C. S., Zeng W., Stoner G. D. Ellagic acid embryoprotection in vitro: distribution and effects on DNA adduct formation. Teratology 1993; 47: 275–280
   PubMedGoogle Scholar
• Frischer H., Bowman J. E., Carson P. E., Rieckmann K. H., Willerson D., Colwell E. J. Erythrocyte glutathione reductase, glucose-6-phosphate dehydrogenase and 6-phosphogluconic dehydrogenase deficiencies in populations of the United States, South Vietnam, Iran and Ethiopia. J. Lab. Clin. Med. 1973; 81: 603
   PubMedGoogle Scholar
• Gibson J. E., Becker B. A. Effect of phenobarbital and SKF 525-A on the teratogenicity of cyclophosphamide in mice. Teratology 1968; 1: 393–398
   PubMedGoogle Scholar
• Gonzalez F. J. Genetic polymorphism and cancer susceptibility. Fourteenth Sapporo Cancer Seminar. Cancer Res. 1995; 55: 710–715
   PubMed Web of Science ®Google Scholar
• Gordon G. B., Spielberg S. P., Blake D. A., Balasubramanian V. Thalidomide teratogenesis: evidence for a toxic arene oxide metabolite. Proc. Natl. Acad. Sci. U.S.A. 1981; 78: 2545–2548
   PubMed Web of Science ®Google Scholar
• Gordon G. B., Spielberg S. P., Blake D. A., Balasubramanian V. Thalidomide teratogenesis: evidence for a toxic arene oxide metabolite. Proc. Natl. Acad. Sci. U.S.A. 1983; 78: 2545–2548
   Google Scholar
• Goto Y., Noda Y., Mori T., Nakano M. Increased generation of reactive oxygen species in embryos cultured in vitro. Free Rad. Biol. Med. 1993; 15: 69–75
   PubMed Web of Science ®Google Scholar
• Greenaway J. C., Fantel A. G. Enhancement of rifampin teratogenicity in cultured rat embryos. Toxicol. Appl. Pharmacol. 1983; 69: 81–88
   PubMed Web of Science ®Google Scholar
• Guengerich F. P., Shimada T. Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. Chem. Res. Toxicol. 1991; 4: 391–407
   PubMed Web of Science ®Google Scholar
• Hales B. F. Modification of the mutagenic-ity and teratogenicity of cyclophosphamide in rats with inducers of the cytochromes P-450. Teratology 1981a; 24: 1–11
   PubMedGoogle Scholar
• Hales B. F. Modification of the teratogenicity and mutagenicity of cyclophosphamide with thiol compounds. Teratology 1981b; 23: 373–381
   PubMedGoogle Scholar
• Halliwell B., Gutteridge J. M. C. Protection against oxidants in biological systems: the superoxide theory of oxygen toxicity. Free Radicals in Biology and Medicine, B. Halliwell, J. M. C. Gutteridge. Oxford University Press, London 1989; 86–187
   Google Scholar
• Halliwell B., Kaur H., Ingelman-Sundberg M. Hydroxylation of salicylate as an assay for hydroxyl radicals: a cautionary note. Free Rod. Biol. Med. 1991; 10: 439–441
   PubMed Web of Science ®Google Scholar
• Hansen D. K. The embryotoxicity of phenytoin: an update on possible mechanisms. Proc. Soc. Exp. Biol Med. 1991; 197: 361–368
   PubMed Web of Science ®Google Scholar
• Harbison R. D. Chemical-biological reactions common to teratogenesis and mutagen-esis. Environ. Health Perspect. 1978; 24: 87–100
   PubMedGoogle Scholar
• Harbison R. D., Becker B. A. Effects of phenobarbital or SKF525A pretreatment on diphenylhydantoin disposition in pregnant mice. Toxicol. Appl. Pharmacol. 1971; 20: 573–581
   PubMed Web of Science ®Google Scholar
• Harbison R. D., Becker B. A. Comparative embryotoxicity of diphenylhydantoin and some of its metabolites in mice. Teratology 1974; 10: 237–242
   PubMedGoogle Scholar
• Harris C., Stark K. L., Juchau M. R. Glutathione status and the incidence of neural tube defects elicited by direct acting terato-gens in vitro. Teratology 1988; 37: 577–590
   PubMedGoogle Scholar
• Harris C., Stark K. L., Luchtel D. L., Juchau M. R. Abnormal neurulation induced by 7-hydroxy-2-acetylaminofluorene and acetaminophen: evidence for catechol metabolites as proximate dysmorphogens. Toxicol. Appl. Pharmacol. 1989; 101: 432–447
   PubMed Web of Science ®Google Scholar
• Heinonen O. P., Slone D., Shapiro S. Birth Defects and Drugs in Pregnancy. PSG., Littleton, MA 1977; 450: 127
   Google Scholar
• High K. A., Kubow S. n-3 fatty acids inhibit defects and fatty acid changes caused by phenytoin in early gestation in mice. Lipids 1994; 29: 771–778
   PubMedGoogle Scholar
• Hiranruengchok R., Harris C. Glutathione oxidation and embryotoxicity elicited by diamide in the developing rat conceptus in vitro. Toxicol. Appl. Pharmacol. 1993; 120: 62–71
   PubMedGoogle Scholar
• Hsieh L.-L., Hsieh T.-T. Detection of aflatoxin B1DNA adducts in human placenta and cord blood. Cancer Res. 1993; 53: 1278–1280
   PubMed Web of Science ®Google Scholar
• Hume R. Proc. 7th Annual Workshop on Glucuronidation and the UDP-Glucurono-syltransferases, Pitlochry, Scotland, 1993, 7
   Google Scholar
• Iyer P., Martin J. E., Irvin T. R. Role of biotransformation in the in vitro preimplan-tation embryotoxicity of naphthalene. Toxicology 1991; 66: 257–270
   PubMedGoogle Scholar
• Jellum E., Marstein S., Skullerud K., Munthe E. Glutathione in pyroglutamic aciduria (5-oxoprolinuria) and rheumatoid arthritis. Functions of Glutathione: Biochemical, Physiological, Toxicological and Clinical Aspects, A. Larsson, S. Orrenius, A. Holmgren, B. Mannervik. Raven Press, New York 1983; 325–336
   Google Scholar
• Jones A. L., Hume R., Bamford K. J., Coughtrie W. H. Estrogen and phenol sulfotransferase activities in human fetal lung. Early Hum. Dev. 1992; 28: 65–77
   PubMed Web of Science ®Google Scholar
• Juchau M. R. Enzymatic bioactivation and inactivation of chemical teratogens and trans-placental carcinogens/mutagens. The Biochemical Basis of Chemical Teratogenesis. Elsevier, New York 1981; 63–94
   Google Scholar
• Juchau M. R., Bark D. H., Shewey L. M., Greenaway J. C. Generation of reactive dysmorphogenic intermediates by rat embryos in culture: effects of cytochrome P-450 inducers. Toxicol. Appl. Pharmacol. 1985a; 81: 533–544
   PubMed Web of Science ®Google Scholar
• Juchau M. R., Giachelli C. M., Fantel A. G., Greenaway J. C., Shepard T. H., Faustman-Watts E. M. Effects of 3-me-thylcholanthrene and phenobarbital on the capacity of embryos to bioactivate teratogens during organogenesis. Toxicol. Appl. Pharmacol. 1985b; 80: 137–147
   PubMed Web of Science ®Google Scholar
• Juchau M. R., Fantel A. G., Harris C., Beyer B. K. The potential role of redox cycling as a mechanism for chemical teratogenesis. Environ. Health Perspect. 1986; 70: 131–136
   PubMed Web of Science ®Google Scholar
• Juchau M. R., Lee Q. P., Fantel A. G. Xenobiotics biotransformation/bioactivation in organogenesis-stage conceptal tissues: implications for embryotoxicity and teratogenesis. Drug Metab. Rev. 1992; 24: 195–238
   PubMed Web of Science ®Google Scholar
• Jurima-Romet M., Shek P. N. Lung uptake of liposome-entrapped glutathione after intratracheal administration. J. Pharm. Pharmacol. 1991; 43: 6–10
   PubMed Web of Science ®Google Scholar
• Kanekal S., Kehrer J. P. Metabolism of cyclophosphamide by lipoxygenases. Drug Metab. Dispos. 1993; 22: 74–78
   Google Scholar
• Kappus H. Overview of enzyme systems involved in bio-reduction of drugs and in redox cycling. Biochem. Pharmacol. 1986; 35: 1–6
   PubMed Web of Science ®Google Scholar
• Keller R. J., Hinson J. A. Mechanism of acetaminophen-stimulated NADPH oxidation catalyzed by the peroxidase-H2O2 system. Drug Metab. Dispos. 1991; 19: 184–187
   PubMed Web of Science ®Google Scholar
• Kim P. M., Wells P. G. Salicylate hy-droxylation as an in vivo probe for hydroxyl radical formation in CD-1 mice: relevance to phenytoin teratogenicity. Toxicologist 1993; 13: 253
   Google Scholar
• Kim P. M., Wells P. G. Phenytoin hydroxyl radical formation: characterization by enhanced salicylate hydroxylation. Mol. Pharmacol. 1996; 49: 172–181
   PubMedGoogle Scholar
• Kim P. K., Winn L. M., Parman T., Wells P. G. Submitted. UDP-glucuronosyltrans-ferase-mediated protection against in vitro DNA oxidation, micronucleus formation and embryotoxicity initiated by phenytoin and its major metabolite 5-(p-hydroxyphenyl)-5-phenylhydantoin (HPPH)
   Google Scholar
• Kitada M., Kamataki T. Cytochrome P450 in human fetal liver: significance and fetal-specific expression. Drug Metab. Rev. 1994; 26: 2305–2323
   Google Scholar
• Kitchin K. T., Schmid B. P., Sanyal M. K. Teratogenicity of cyclophosphamide in a coupled microsomal activating/embryo culture system. Biochem. Pharmacol. 1981; 30: 59–64
   PubMed Web of Science ®Google Scholar
• Kromidas L., Trombetta L. D., Jamall I. S. The protective effects of glutathione against methyl mercury cytotoxicity. Toxicol. Lett. 1990; 51: 67–80
   PubMed Web of Science ®Google Scholar
• Kubow S. Inhibition of isotretinoin teratogenicity by acetylsalicylic acid pretreatment in mice. Teratology 1992; 45: 55–63
   PubMedGoogle Scholar
• Kubow S., Wells P. G. In vitro evidence for prostaglandin synthetase-catalyzed bio-activation of phenytoin to a free radical intermediate. Pharmacologist 1986; 28: 195
   Google Scholar
• Kubow S., Wells P. G. In vitro evidence for lipoxygenase-catalyzed bioactivation of phenytoin. Pharmacologist 1988; 30: A74
   Google Scholar
• Kubow S., Wells P. G. In vitro bioactivation of phenytoin to a reactive free radical intermediate by prostaglandin syn-thetase, horseradish peroxidase and thyroid peroxidase. Mol. Pharmacol. 1989; 35: 504–511
   PubMed Web of Science ®Google Scholar
• Laposa R. R., Wells P. G. Preliminary evaluation of phenytoin teratogenicity in transgenic mice deficient in the p53 tumor suppressor gene. Toxicologist 1995; 15: 161
   Google Scholar
• Laposa R. L., Chan K. C., Wilewy M. J., Wells P. G. Enhanced phenytoin embryopathy in p53-deficient mice: characterisation of embryonic p53 genotype and the p53, p21 and Bax DNA damage response proteins. Toxicologist 1996; 16: 997
   Google Scholar
• Larsson A., Hagenfeldt L. Hereditary glutathione synthetase deficiency in man. Functions of Glutathione: Biochemical, Physiological, Toxicological, and Clinical Aspects, A. Larsson, S. Orrenius, A. Holmgren, B. Hannervik. Raven Press, New York 1983; 317–324
   Google Scholar
• Lear L., Nation R. L., Stupans I. Effects of cyclophosphamide and adriamycin on rat hepatic microsomal glucuronidation and lipid peroxidation. Biochem. Pharmacol. 1992; 44: 747–753
   PubMed Web of Science ®Google Scholar
• Lenz W. Kindliche Missbildungen nach Medikament-Einnahme wahrend der Gravid-itat. Dtsch. Med. Wochenschr. 1961; 86: 2555–2556
   Web of Science ®Google Scholar
• Lenz W. Thalidomide and congenital anomalies. Lancet 1962; 1: 45
   Web of Science ®Google Scholar
• Little S. A., Mirkes P. E. DNA cross-linking and single-strand breaks induced by teratogenic concentrations of 4-hydro-peroxycyclophosphamide and phosphoramide mustard in postimplantation rat embryos. Cancer Res. 1987; 47: 5421–5426
   PubMed Web of Science ®Google Scholar
• Liu L., Wells P. G. In vitro and in vivo cytochromes P450- and peroxidase-catalysed formation of phenytoin-DNA adducts in mu-rine maternal hepatic and embryonic tissues. Proc. 10th International Symposium on Microsomes and Drug Oxidations. Toronto, Canada July, 1994a; 555
   Google Scholar
• Liu L., Wells P. G. In vivo phenytoin-initiated oxidative damage to proteins and lip-ids in murine maternal hepatic and embryonic tissue organelles: potential molecular targets mediating chemical teratogenesis. Toxicol. Appl. Pharmacol. 1994b; 125: 247–255
   PubMedGoogle Scholar
• Liu L., Wells P. G. Potential molecular targets mediating chemical teratogenesis: in vitro peroxidase-catalysed phenytoin metabolism and oxidative damage to proteins and lipids in murine maternal hepatic microsomes and embryonic 9000 g supernatant. Toxicol. Appl. Pharmacol. 1995a; 134: 71–80
   PubMed Web of Science ®Google Scholar
• Liu L., Wells P. G. DNA oxidation as a potential molecular mechanism mediating drug-induced birth defects: phenytoin and structurally related teratogens initiate the formation of 8-hydroxy-2'-deoxyguanosine in vitro and in vivo in murine maternal hepatic and embryonic tissues. Free Rad. Biol. Med. 1995b; 19: 639–648
   PubMed Web of Science ®Google Scholar
• Loch-Caruso R., Baxter C. S. DNA damage and repair in embryonic mouse limbs exposed to teratogenic doses of methyl-nitrosourea. Mutat. Res. 1984; 131: 147–155
   PubMed Web of Science ®Google Scholar
• Loiseau P., Duche B. Potential antiepileptic drugs: stiripentol. Antiepileptic Drugs3rd, R. Levy, R. Mattson, B. Meldrum, J. K. Penry, F. E. Dreifuss. Raven Press, New York 1989; 955–969
   Google Scholar
• Lu L.-J. W., Anderson L. M., Jones A. B., Moskal T. J., Salazar J. J., Hokanson J. A., Rice J. M. Persistence, gestation stage-dependent formation and interrelationship of benzo[a]pyrene-induced DNA adducts in mothers' placentae and fetuses of erythroceubs patas monkeys. Carcinogenesis 1993; 14: 1805–1813
   PubMed Web of Science ®Google Scholar
• Lum J. T., Wells P. G. Pharmacological studies on the potentiation of phenytoin ter-atogenicity by acetaminophen. Teratology 1986; 33: 53–72
   PubMedGoogle Scholar
• Manson J. Teratogens. Toxicology, The Basic Science of Poisons, C. D. Klaassen, M. D. Amdur, J. Doull. Macmillan, New York 1986; 195–220
   Google Scholar
• Marnett L. J., Wlodawer P., Samuelsson B. Co-oxygenation of organic substrates by prostaglandin synthetase of sheep vesicular gland. J. Biol. Chem. 1975; 250: 8510–8517
   PubMed Web of Science ®Google Scholar
• Marnett L. J., Reed G. A., Johnson J. T. Prostaglandin synthase-dependent benzo[a]pyrene oxidation: products of the oxidation and inhibition of their formation by antioxidants. Biochem. Biophys. Res. Commun. 1977; 79: 569–576
   PubMed Web of Science ®Google Scholar
• Marnett L. J., Reed G. A., Dennison D. J. Prostaglandin synthase dependent activation of 7,8-dihydro-7,8-dihydroxylbenzo[a] pyrene to mutagenic derivatives. Biochem. Biophys. Res. Commun. 1978; 82: 210–216
   PubMed Web of Science ®Google Scholar
• Marnett L. J. Prostaglandin synthase mediated metabolism of carcinogens and a potential role for peroxyl radicals as reactive intermediates. Environ. Health Perspect. 1990; 88: 5–12
   PubMedGoogle Scholar
• Martz F., Failinger C., Blake D. A. Phenytoin teratogenicity: correlation between embryopathic effect and covalent binding of putative arene oxide metabolite in gestational mouse. J. Pharmacol. Exp. Ther. 1977; 203: 231–239
   PubMed Web of Science ®Google Scholar
• McBride. Thalidomide and congenital abnormalities. Lancet 1961; 2: 1358
   Web of Science ®Google Scholar
• Mehta A. B. Glucose-6-phosphate dehydro-genase deficiency. Postgrad. Med. J. 1994; 70: 871–877
   PubMedGoogle Scholar
• Meister A. Metabolism and transport of glutathione and other gamma-glutamyl compounds. Functions of Glutathione: Biochemical, Physiological, Toxicological, and Clinical Aspects, A. Larsson, S. Orrenius, A. Holmgren, B. Mannervik. Raven Press, New York 1983; 1–93
   Google Scholar
• Miranda A. F., Wiley M. J., Wells P. G. Evidence for embryonic peroxidase-catalysed bioactivation and glutathione-depen-dent cytoprotection in phenytoin teratogenic-ity: modulation by eicosatetraynoic acid and buthionine sulfoximine in murine embryo culture. Toxicol. Appl. Pharmacol. 1994; 124: 230–241
   PubMed Web of Science ®Google Scholar
• Mirkes P. E., Little S. A., Beland F. A., Huitfeldt H. S., Poirier M. C. Quantitation and immunohistochemical localization of DNA adducts in rat embryos and associated yolk sac membranes exposed in vitro to N -acetoxy-2-acetylaminofluorene (N-Ac-AAF). Teratogen. Carcinogen. Mutagen. 1991; 11: 93–102
   PubMedGoogle Scholar
• Modrich P. Mismatch repair, genetic stability and tumour avoidance. Philos. Trans. R. Soc. London Ser. B. 1995; 347: 89–95
   PubMedGoogle Scholar
• Nau H. Retinoidteratogenesis: toxicokinetics and structure-specificity. Arch. Toxicol. 1994; 16(Suppl)118–127
   Google Scholar
• Nebert D. W. Genetic differences in drug metabolism: proposed relationship to human birth defects. Handbook of Experimental Pharmacology Teratogenesis and Reproductive Toxicology, E. M. Johnson, D. M. Kochhar. Springer-Verlag, New York 1983; 65: 49–62
   Google Scholar
• New D. A. T. Whole embryo culture and the study of mammalian embryos during organo-genesis. Biol. Rev. 1978; 53: 81–122
   PubMed Web of Science ®Google Scholar
• Nicol C. J., Harrison M. L., Laposa R. R., Gimelshtein I. L., Wells P. G. A teratologic suppressor role for p53 in benzo[a]pyrene-treated transgenic p53-defi-cient mice. Nature Genet. 1995; 10: 181–187
   PubMed Web of Science ®Google Scholar
• Nicol C. J., Wells P. G. Glucose-6-phosphate dehydrogenase (G6PD): an embryo-protective role in endogenous oxidative stress and phenytoin teratogenesis. Toxicologist 1996; 16: 1008
   Google Scholar
• Nishikido N., Furuyashiki K., Naganuma A., Suzuki T., Imura N. Maternal selenium deficiency enhances the fetolethal tox-icity of methyl mercury. Toxicol. Appl. Pharmacol. 1987; 88: 322–328
   PubMed Web of Science ®Google Scholar
• Nonogaki T., Noda Y., Narimoto K., Umaoka Y., Mori T. Effects of superoxide dismutase on mouse in vitro fertilization and embryo culture system. J. Assist. Reprod. Genet. 1992; 9: 274–280
   PubMedGoogle Scholar
• Noda Y., Matsumoto H., Mori T. Superoxide dismutase overcomes 2-cell block in mouse embryos. Acta. Obstet. Gynaecol. Jpn. 1989; 41: 751–752
   Google Scholar
• Noda Y., Matsumoto H., Umaoka Y., Tatsumi K., Kishi J., Mori T. Involvement of superoxide radicals in the mouse 2-cell block. Mol. Reprod. Dev. 1991; 28: 356–360
   PubMed Web of Science ®Google Scholar
• Otto S., Marcus C., Pidgeon C., Jefcoate C. A novel adrenocorticotrophin-inducible cytochrome P450 from rat adrenal microsomes catalyzes polycyclic aromatic hydrocarbon metabolism. Endocrinology 1991; 129: 970–982
   PubMed Web of Science ®Google Scholar
• Otto S., Bhattacharyya K. K., Jefcoate C. R. Polycyclic aromatic hydrocarbon metabolism in rat adrenal, ovary and testis microsomes is catalyzed by the same novel cytochrome P450 (P450RAP). Endocrinology 1992; 131: 3067–3076
   PubMed Web of Science ®Google Scholar
• Ornaghi F., Ferrini S., Pratt M., Giavini E. The protective effects of N-acetyl-L-cys-teine against methyl mercury embryotoxicity in mice. Fundam. Appl. Toxicol. 1993; 20: 437–445
   PubMedGoogle Scholar
• Ozolins T. R. S., Oglesby L. A., Wiley M. J., Wells P. G. In vitro murine embryopathy of cyclophosphamide in embryos co-cultured with maternal hepatocytes: development and application of a murine embryo-hepatocyte co-culture model. Toxicology 1995a; 102: 259–274
   PubMed Web of Science ®Google Scholar
• Ozolins T. R. S., Wiley M. J., Wells P. G. Phenytoin covalent binding and embryopathy in murine embryos co-cultured with maternal hepatocytes from mouse, rat and rabbit. Biochem. Pharmacol. 1995b; 50: 1831–1840
   PubMedGoogle Scholar
• Ozolins T. R. S., Siksay D. L. A., Wells P. G. Selenium-dependent modulation of glutathione peroxidase activities and phenytoin teratogenicity. J. Pharmacol. Exp. Ther. 1996, In press.
   PubMedGoogle Scholar
• Panich V. G6PD variants in southern Asian populations. Glucose-6-phosphate Dehy-drogenase, A. Yoshida, E. Beutler. Academic Press, New York 1986; 195–241
   Google Scholar
• Pantarotto C., Arbix M., Sezzano P., Abbruzzi R. Studies on 5,5-diphenyl hydantoin irreversible binding to rat liver mi-crosomal proteins. Biochem. Pharmacol. 1982; 31: 1501–1507
   PubMed Web of Science ®Google Scholar
• Parman T., Chen G., Bray T. M., Wells P. G. Bioactivation of phenytoin, thali-domide and related teratogens to a free radical intermediate using prostaglandin H synthase (PHS) or hepatic microsomes: characterization by electron spin resonance (ESR) spec-trometry. Toxicologist 1996; 16: 1260
   Google Scholar
• Pillans P. I., Ponzi S. F., Parker M. I. Cyclophosphamide induced DNA strand breaks in mouse embryo cephalic tissue in vivo. Carcinogenesis 1989; 10: 83–85
   PubMedGoogle Scholar
• Platzek T., Bochert G., Meister R., Neubert D. Embryotoxicity induced by alkylat-ing agents. VII. Low dose prenatal-toxic risk estimation based on NOAEL risk factor approach, dose-response. Relationships and DNA adducts using methylnitrosourea as a model compound. Teratogen. Carcinogen. Mutagen. 1993; 13: 101–125
   PubMedGoogle Scholar
• Platzek T., Bochert G., Rahm T. Embryotoxicity induced by alkylating agents. VIII. DNA adduct formation induced by ethylmethanesulfonate in mouse embryos. Teratogen. Carcinogen. Mutagen. 1994a; 14: 65–73
   PubMedGoogle Scholar
• Platzek T., Schwabe R., Rahm U., Bochert G. DNA modification induced by 6-mercaptopurine riboside in murine embryos. Chem. Biol. Interact. 1994b; 93: 59–71
   PubMedGoogle Scholar
• Platzek T., Bochert G., Pauli B., Meister R., Neubert D. Embryotoxicity induced by alkylating agents: 5 dose-response relationships of teratogenic effects of methylnitrosourea in mice. Arch. Toxicol. 1988; 62: 411–423
   PubMedGoogle Scholar
• Ponz, De Leon M. Cancer-prone hereditary diseases associated with abnormalities of DNA repair. Recent Res. Cancer 1994; 136: 322–331
   PubMedGoogle Scholar
• Pottenger L. H., Christou M., Jefcoate C. R. Purification and immunological characterization of a novel cytochrome P450 from C3H/10T1/2 Cells. Arch. Biochem. Biophys. 1991; 286: 488–497
   PubMed Web of Science ®Google Scholar
• Potter D. W., Hinson J. A. Mechanisms of acetaminophen oxidation to N-acetyl-p-benzoquinone imine by horseradish peroxi-dase and cytochrome P450. J. Biol. Chem. 1987; 262: 966–973
   PubMed Web of Science ®Google Scholar
• Radman M., Matic I., Halliday J. A., Taddei F. Editing DNA replication and recombination by mismatch repair: from bacterial genetics to mechanisms of predisposition to cancer in humans. Philos. Trans. R. Soc. London Ser. 1995; B347: 97–103
   Google Scholar
• Raucy J. L., Carpenter S. J. The expression of xenobiotic-metabolizing cytochromes P450 in fetal tissues. J. Pharmacol. Toxicol. Methods 1993; 29: 121–128
   PubMed Web of Science ®Google Scholar
• Roberts C. J., Lowe C. R. Where have all the conceptions gone. Where have all the conceptions gone 1975; 1: 498–499
   Google Scholar
• Rolfe B. E. Detection of fetal wastage. Fertil. Steril. 1982; 37: 655–660
   PubMed Web of Science ®Google Scholar
• Roy D., Snodgrass W. R. Covalent binding of phenytoin and modulation of diphenylhydantoin metabolism by thiols in A/J mouse liver microsomes. J. Pharmacol. Exp. Ther. 1990; 252: 895–900
   PubMed Web of Science ®Google Scholar
• Roy S. K., Kulkarni A. P. Lipoxygenase: a new pathway for 2-aminofluorene bioactivation. Cancer Lett. 1991; 60: 33–39
   PubMedGoogle Scholar
• Saillenfait A.-M., Payan J.-P., Langonne I., Beydon D., Grandclaude M.-C., Sabate J.-P., De Ceaurriz J. Modulation of acry-lonitrile-induced embryotoxicity in vitro by glutathione depletion. Arch. Toxicol. 1993; 67: 164–172
   PubMed Web of Science ®Google Scholar
• Samokyszyn V. M., Sloane B. F., Honn K. V., Mamett L. J. Cooxidation of 13-cis-retinoic acid by prostaglandin H synthase. Biochem. Biophys. Res. Commun. 1984; 124: 430–436
   PubMed Web of Science ®Google Scholar
• Sancar A. Mechanisms of DNA excision repair. Science 1994; 266: 1954–1956
   PubMed Web of Science ®Google Scholar
• Sanyal M. K., Kitchin K. T., Dixon R. L. Anomalous development of rat embryos cultured in vitro with cyclophosphamide and microsomes. Pharmacologist 1979; 21: 231
   Google Scholar
• Sanyal S., Wells P. G. Reduction in phenytoin teratogenicity by pretreatment with the antioxidant d-a-tocopherol acetate (vitamin E) in CD-1 mice. Toxicologist 1993; 13: 252
   Google Scholar
• Sato J. Glutathione S-transferases and hepatocarcinogenesis. Jpn. J. Cancer Res. 1988; 79: 556–572
   PubMedGoogle Scholar
• Savas U., Bhattacharyya K. K., Christou M., Alexander D. L., Jefcoate C. R. Mouse cytochrome P-450EF, representative of a new 1B subfamily of cytochrome P-450s. J. Biol Chem. 1994; 269: 14905–14911
   PubMed Web of Science ®Google Scholar
• Shanks M. J., Wiley M. J., Kubow S., Wells P. G. Phenytoin teratogenicity: role of enzymatic bioactivation in a murine embryo culture model. Teratology 1989; 40: 311–320
   PubMedGoogle Scholar
• Shum S., Jensen N. M., Nebert D. W. The murine Ah locus: in utero toxicity and teratogenesis associated with genetic differences in benzo[a]pyrene metabolism. Teratology 1979; 20: 365–376
   PubMedGoogle Scholar
• Slott V. L., Hales B. F. Enhancement of the embryotoxicity of acrolein, but not phosphoramide mustard by glutathione depletion in rat embryos in vitro. Biochem. Pharmacol. 1987; 36: 2019–2025
   PubMed Web of Science ®Google Scholar
• Smith R. G., Daves G. D., Jr, Lynn R. K., Gerber N. Hydantoin ring glucuroni-dation: characterization of a new metabolite of 5,5-diphenyl hydantoin in man and the rat. Biomed. Mass Spectrom. 1977; 4: 275–279
   PubMedGoogle Scholar
• Spielberg S. P. Acetaminophen toxicity in lymphocytes heterozygous for glutathione syn-thetase deficiency. Can. J. Physiol. Pharmacol. 1985; 63: 468–471
   PubMedGoogle Scholar
• Stark K. L., Harris C., Juchau M. R. Embryotoxicity elicited by inhibition of gamma-glutamyltransferase by acivicin and transferase antibodies in cultured rat embryos. Toxicol. Appl. Pharmacol. 1987; 89: 88–97
   PubMedGoogle Scholar
• Strickler S. M., Dansky L. V., Miller M. A., Seni M. H., Andermann E., Spielberg S. P. Genetic predisposition to phenytoin induced birth defects. Lancet 1985; 2: 746–749
   PubMed Web of Science ®Google Scholar
• Suntres Z. E., Shek P. N. Incorporation of a-tocopherol in liposomes promotes the retention of liposome-encapsulated glutathione in the rat lung. J. Pharm. Pharmacol. 1994; 46: 23–28
   PubMed Web of Science ®Google Scholar
• Terlouw G. D. C., Namkung M. J., Juchau M. R., Bechter R. F. In vitro embryotoxicity of N -methyl-N-(7-propoxynaphtha-lene-2-ethyl)-hydroxylamine (QAB): evidence for Af-dehydroxylated metabolite as a proximate dysmorphogen. Teratology 1993; 48: 431–439
   PubMedGoogle Scholar
• Tonoki H. Establishment of Chinese hamster ovary cell lines with reduced expression of glutathione reductase after antisense-ori-ented gene transfection and assessment of the sensitivity to oxidant injury. Hokkaido J. Med. Sci. 1994; 69: 1261–1274
   PubMedGoogle Scholar
• Uetrecht J., Zahid N. N-chlorination of phenytoin by myeloperoxidase to a reactive metabolite. Chem. Res. Toxicol. 1988; 1: 148–151
   PubMed Web of Science ®Google Scholar
• Veronese M. E., Mackenzie P. I., Doecke C. J., McManus M. E., Miners J. O., Birkett D. J. Tolbutamide and phenytoin hy-droxylations by cDNA-expressed human liver cytochrome P4502C9. Biochem. Biophys. Res. Commun. 1991; 3: 1112–1118
   Google Scholar
• Vienneau D. S., DeBoni U., Wells P. G. Potential genoprotective role for UDP-glucuronosyltransferases (UGTs) in chemical carcinogenesis: initiation of micronuclei by benzo[a]pyrene and benzo[e]pyrene in UGT-deficient cultured rat skin fibroblasts. Cancer Res. 1995; 55: 1045–1051
   PubMed Web of Science ®Google Scholar
• Wang M. Y., Lu L. J. W. Differential effect of gestation stage on benzo[a]pyrene-induced micronucleus formation and/or cova-lent DNA modifications in mice. Cancer Res. 1990; 50: 2146–2151
   PubMedGoogle Scholar
• Wells P. G., Gesicki I. B. Modulation of phenytoin teratogenicity by exogenous and endogenous inhibitors of oxidative drug metabolism. Proceedings of the 9th International Congress of Pharmacology. London, U.K 1984; 1772
   Google Scholar
• Wells P. G. Chemical teratogenesis. Principles of Medical Pharmacology, 5th, H. Kalant, W. H. E. Roschlau. B. C. Decker, Toronto 1989; 644–657
   Google Scholar
• Wells P. G., Vo H. P. N. Effect of the tumor promoter 12-O-tetradecanoylphorbol-13-acetate (TPA) on phenytoin embryopathy. Toxicol. Appl. Pharmacol. 1989; 97: 398–405
   PubMed Web of Science ®Google Scholar
• Wells P. G., Harbison R. D. Significance of the phenytoin reactive arene oxide intermediate, its oxepin tautomer, and clinical factors modifying their role in phenytoin-in-duced teratology. Phenytoin-Induced Teratology and Gingival Pathology, T. M. Hassell, M. C. Johnston, K. H. Dudley. Raven Press, New York 1980; 83–108
   Google Scholar
• Wells P. G., Obilo F. C., De Morais S. M. F. Benzo[a]pyrene embryopathy in rats genetically deficient in bilirubin UDP-glucuronyl transferase. FASEB J. 1989a; 3: A1025
   Google Scholar
• Wells P. G., Nagai M. K., Spano Greco G. Inhibition of trimethadione and dimethadione teratogenicity by the cyclo-oxygenase inhibitor acerylsalicylic acid: a unifying hypothesis for the teratologic effects of hydantoin anticonvulsants and structurally related compounds. Toxicol. Appl. Pharmacol. 1989b; 97: 406–414
   PubMed Web of Science ®Google Scholar
• Wells P. G., Zubovits J. T., Wong S. T., Molinari L. M., Ali S. c. Modulation of phenytoin teratogenicity and embryonic cova-lent binding by acetylsalicylic acid, caffeic acid and alpha-phenyl-N-t-butylnitrone: implications for bioactivation by prostaglandin synthetase. Toxicol. Appl. Pharmacol. 1989; 97: 192–202
   PubMed Web of Science ®Google Scholar
• Wells P. G., Davidovich O., Mark T. M. Inhibition of murine phenytoin teratogenicity by the iron chelator deferoxamine. Toxicologist 1991; 11: 293
   Google Scholar
• Wells P. G., Srivastava S. Enhancement of phenytoin fetal and maternal toxicity by low-level exposure to methylmercury. Toxicologist 1992; 12: 309
   Google Scholar
• Wells P. G., Williams L. M. Effect of phenytoin on embryonic soluble thiols and disulfides in murine embryo culture. Toxicologist 1994; 14: 164
   Google Scholar
• Wells P. G., Leeder J. S., Winn L. M. Phenytoin-initiated protein oxidation in murine embryo culture: a potential molecular mechanism mediating phenytoin teratogenicity. Toxicologist 1995; 15: 276
   Google Scholar
• Wells P. G., Kim P. M. UDP-glucuronosyltransferase (UGT)-mediated genoprotection in phenytoin- and 5-(p-hydroxyphenyl)-5-phenylhydantoin (HPPH)-initiated DNA oxidation and micronucleus formation. Toxicologist 1996; 16: 1201
   Google Scholar
• Wells P. G., Kim P. M., Nicol C. J., Parman T., Winn L. M. Reactive intermediates. Handbook of Experimental Pharmacology: Drug Toxicity in Embryonic Development chap. 17, R. J. Kavlock, G. P. Daston. Springer-Verlag, in press, Heidelberg 1996
   Google Scholar
• Williams G. M., Weisburger J. H. Chemical carcinogenesis. Casarett and Doull's Toxicology: The Basic Science of Poisons, 4th, M. O. Amdur, J. Doull, C. D. Klaassen. McGraw-Hill, New York 1991; 127–200
   Google Scholar
• Wilson J. G. Present status of drugs as teratogens in man. Teratology 1973; 7: 3–16
   PubMedGoogle Scholar
• Winn L. M., Wells P. G. Benzo[a] pyrene-initiated DNA and protein oxidation in murine embryo culture: a potential molecular mechanism mediating benzo[a]pyrene teratogenicity. Proc. 27th Annual Symposium of the Society of Toxicology of Canada. 1994; 77
   Google Scholar
• Winn L. M., Wells P. G. Free radical-mediated mechanisms of anticonvulsant teratogenicity. Eur. J. Neurol. 1995a; 2((Suppl. 4))5–29
   PubMedGoogle Scholar
• Winn L. M., Wells P. G. Phenytoin-initiated DNA oxidation in murine embryo culture, and embryoprotection by the anti-oxidative enzymes superoxide dismutase and catalase: evidence for reactive oxygen species mediated DNA oxidation in the molecular mechanism of phenytoin teratogenicity. Mol. Pharmacol. 1995b; 48: 112–120
   PubMed Web of Science ®Google Scholar
• Winn L. M., Wells P. G. Enhancement of embryonic activity of superoxide dismutase (SOD) and inhibition of benzo[a]pyrene embryopathy in embryo culture by exogenous addition of SOD. Toxicologist 1996; 16: 1249
   Google Scholar
• Winn L. M., Wells P. G. Evidence for embryonic prostaglandin H synthase-catalyzed bioactivation and reactive oxygen species-mediated oxidation of macromolecules in phenytoin and benzo[a]pyrene teratogenesis. Free Rad. Biol. Med. 1996, In press
   Web of Science ®Google Scholar
• Wong M., Wells P. G. Effects of N -acetylcysteine on fetal development and phenytoin teratogenicity in mice. Teratogen. Carcinogen. Mutagen. 1988; 8: 65–79
   PubMedGoogle Scholar
• Wong M., Wells P. G. Modulation of embryonic glutathione reductase and phenytoin teratogenicity by l,3-bis(2-chloroethyl)-l-nitrosourea. J. Pharmacol. Exp. Ther. 1989; 250: 336–342
   PubMed Web of Science ®Google Scholar
• Wong M., Helston L. M. J., Wells P. G. Enhancement of murine phenytoin teratogenicity by the gamma-glutamylcysteine synthetase inhibitor buthionine sulfoximine and the glutathione depletor diethylmaleate. Teratology 1989; 40: 127–141
   PubMedGoogle Scholar
• Wrighton S. A., Stevens J. C. The human hepatic cytochromes P450 involved in drug metabolism. Crit. Rev. Toxicol. 1992; 22: 1–21
   PubMed Web of Science ®Google Scholar
• Wubah J. A., Ibrahim M. M., Gao X., Nguyen D., Pisano M. M., Knudsen T. B. Ter-atogen-induced eye defects mediated by p53-dependent apoptosis. Curr. Biol. 1996; 6: 60–69
   PubMed Web of Science ®Google Scholar
• Yang H.-Y. L., Lee Q. P., Rettie A. E., Juchau M. R. Functional cytochrome P4503A isoforms in human embryonic tissues: expression during organogenesis. Mol. Pharmacol. 1994; 46: 922–928
   PubMed Web of Science ®Google Scholar
• Yoneyama M., Ogata A., Hiraga K. Irreversible in vivo binding of thiabendazole to macromolecules in pregnant mice and its relation to teratogenicity. Fd. Chem. Toxic. 1985; 23: 733–736
   PubMed Web of Science ®Google Scholar
• Yoneyama M., lchikawa H. Irreversible in vivo and in vitro binding of thiabendazole to tissue protein of pregnant mice. Fd. Chem. Toxic. 1986; 24: 1283–1286
   PubMed Web of Science ®Google Scholar
• Yu W. K., Wells P. G. Evidence for lipoxygenase-catalyzed bioactivation of phenytoin to a teratogenic reactive intermediate: in vitro studies using linoleic acid-dependent soybean lipoxygenase, and in vivo studies using pregnant CD-1 mice. Toxicol. Appl. Pharmacol. 1995; 131: 1–12
   PubMed Web of Science ®Google Scholar
• Ziegler M. H., Grafton T. F., Hansen D. K. The effect of tolbutamide on rat embryonic development in vitro. Teratology 1993; 48: 45–51
   PubMedGoogle Scholar
• Zimmerman E. F., Potturi R. B., Resnick E., Fisher J. E. Role of oxygen free radicals in cocaine-induced vascular disruption in mice. Teratology 1994; 49: 192–201
   PubMedGoogle Scholar